ClinicalTrials.gg

Cognitive Dysfunction clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,878 studies for Cognitive Dysfunction across more than 10 countries. 1,120 are recruiting or about to start. 1,915 of them are mainly about Cognitive Dysfunction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Postoperative Cognitive Complications: 4,128 studies, 1,179 open.

ClinicalTrials.gov finds 5,343 studies for Cognitive Dysfunction. How that becomes 3,876 here

This page counts the studies the registry files under Cognitive Dysfunction, and those it files under no condition that list Cognitive Dysfunctionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 5,343Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −250Filed under a narrower condition, counted on its own pagePostoperative Cognitive Complications 221 · Chemotherapy-Related Cognitive Impairment 26
  3. −86List Cognitive Dysfunction as a condition, but the registry did not file them under itMost often written as “Vascular Cognitive Impairment” (14), “Amnestic Mild Cognitive Impairment” (7), and “Post-stroke Cognitive Impairment” (6). The registry filed them under other conditions only, most often Alzheimer Disease (25) and Stroke (13).
  4. −1,134Match it another way492 name it in the title, 45 in a keyword, and 597 by a synonym or other text the search reads.
  5. 3,873Counted here and found by its search81 of them list Cognitive Dysfunction in their own words; the registry filed them under no condition.
  6. +3
    Counted here, but its search does not find them
  7. 3,876The count on this page

Status

Completed
1,834
Recruiting
753
Status unknown
445
Not yet recruiting
282
Active, not recruiting
229
Terminated
159

Phase

Phase 2
383
Phase 1
160
Phase 3
137
Phase 4
130
Early Phase 1
38

Where

United States
1,420
China
309
Canada
224
France
189
Italy
174
Spain
161

Who develops what

Add Cognitive Dysfunction to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 26 programs from 24 companies, 13 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Eli Lilly and Arctic Therapeutics here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
[18F]Fluorbetazine injection☆ Track1 live phase-3 study: NCT07764679HTA Co., Ltd.
donanemabApproved: US 2024 · EU 2025☆ Track2 live phase-3 studies: NCT05508789, NCT04437511Eli Lilly and Company

The 2 in phase 3 with the nearest primary completion, of 26 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 25 Feb 2027 est.GE-287 · GE Healthcare · Phase 2 main aimNCT07873463 Flutemetamol F 18 Injection Formulation Comparison — primary endpoint: Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region · 20 enrolled
  • Apr 2027 est.benzgalantamine gluconate · Alpha Cognition, Inc · Phase 4 registry mapping onlyNCT07633470 A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) — primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) · 150 enrolled
  • 30 Apr 2027 est.N-Acetylcysteinamide · Arctic Therapeutics · Phase 2 main aimNCT07741526 Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) — primary endpoint: Incidence of Treatment -Emergent Adverse Events · 33 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cognitive Dysfunction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Cholinesterase inhibitors 4 open · Stimulants 4 open · SGLT2 inhibitors 3 open · Antimuscarinics 3 open · Reverse transcriptase inhibitors 2 open

Coming up

415studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger. 46 (6%) take children under 18. 16 (2%) are for women only and 1 (<1%) for men only; 260 (35%) take healthy volunteers.

Recruiting studies that take each age, of 753
AgeWomenMen
1033 (4%)31 (4%)
18239 (32%)232 (31%)
30266 (35%)257 (34%)
40307 (41%)295 (39%)
50442 (59%)429 (57%)
65687 (91%)675 (90%)
75658 (87%)649 (86%)
85535 (71%)526 (70%)

Across all 3,876 studies, recruiting or not: 21% stop at 75 or younger and 13% at 65; 5% take children; 3% are for women only and 1% for men only; 35% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cognitive Dysfunction studies take

Of 186 phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 127 mo13–49 · 80 studies17 mo7–40 · 26 studies43 mo16–64 · 54 studies
Phase 1/234 mo12–52 · 25 studies——
Phase 242 mo22–62 · 186 studies24 mo14–39 · 41 studies53 mo29–64 · 145 studies
Phase 344 mo33–63 · 49 studies——
Phase 455 mo20–69 · 51 studies—55 mo27–69 · 43 studies
Interventional, no phase27 mo12–50 · 1,518 studies15 mo7–35 · 69 studies27 mo13–51 · 1,449 studies
Observational47 mo21–118 · 544 studies—49 mo22–118 · 505 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 17, 2026.

Newly registered29

Show 24 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,878. Browse all 3,878 → or search them.